A Safety, Tolerability and Efficacy Study of E7070 in Patients With Renal Cell Carcinoma

Carcinoma, Renal Cell Clinical Trial

Official title:

A Phase II Study of E7070 in Patients With Progressive Inoperable and/or Metastatic Renal Cell Carcinoma (RCC)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00059735
• Other study ID #: E7070-A001-206
• Status: Completed
• Phase: Phase 2
• First received: May 5, 2003
• Last updated: February 29, 2008
• Start date: May 2002
• Est. completion date: December 2003

Study information

• Verified date: February 2008
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if E7070 is a safe and effective treatment for cancer of the kidneys.

Description:

Renal Cell Carcinoma (RCC) accounts for approximately 2% of all cancers and its incidence is increasing with worldwide deaths of over 100,000 patients per year. About 50% of RCC patients have inoperable or metastatic disease that surgery cannot be performed on. RCC is also considered to be resistant to both radiotherapy and cytotoxic chemotherapy. The purpose of this study is to evaluate the safety and effectiveness of E7070 by assessing progression free survival, tumor response rate, duration of response/stable disease, and survival time. E7070 will be administered as a single iv infusion over 60 minutes on Day 1 of each cycle. Patients will continue treatment with E7070 until they no longer have clinical benefit and have disease progression, or toxicity leads to patient withdrawal.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: December 2003
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age >=18 years old.

• Have histologically/cytologically confirmed clear cell RCC.

• Previously untreated or one prior treatment with immunotherapy (one prior treatment may be represented by single agent interferon, single agent interleukin-2 or a combination of interferon with interleukin-2 with or without accompanying hematological growth factors).

• Documented evidence of progressive disease in the previous 3 months. In the absence of radiographic studies, patients may be entered on the study if they have clinical evidence of progressive disease.

• Have at least one unidimensional measurable lesion of RCC according to the RECIST guidelines. The following will not qualify as measurable lesions: bone, leptomeningeal disease, ascites, pleural/pericardial effusion, lymphangitis cutis/pulmonis, abdominal masses that are not confirmed and followed by imaging techniques, and cystic lesions.

• Be ambulatory and have a Karnofsky performance status >=70%.

• Have a life expectancy of at least 3 months.

• Give written informed consent prior to any study-specific screening procedures, with the understanding that the consent may be withdrawn by the patient at any time without prejudice.

• Be willing and able to comply with the study protocol for the duration of the study.

Exclusion Criteria:

• Woman who are pregnant or breastfeeding. Women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test. Women of childbearing potential unless (1) surgically sterile or (2) using adequate contraceptive measures (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential).

• Fertile male subjects not willing to use contraception and whose female partners are not under adequate contraceptive protection.

• Known CNS metastases (if clinical suspicion of CNS metastases exists appropriate imaging must be performed prior to study entry).

• Prior treatment with chemotherapy (there is no restriction on prior epidermal growth factor directed therapy).

• Severe and uncontrolled cardiac or cardiovascular abnormalities.

• Severe uncontrolled intercurrent infections.

• Subjects with organ allografts.

• Any of the following abnormal screening hematological values: Hemoglobin (Hb) <9g /dL (6 mmol/L), Neutrophils <1.5 x 10^9/L, Platelets <100 x 10^9/L.

• Blood transfusions or growth factors to aid hematological recovery within 2 weeks prior to starting study treatment.

• Any of the following abnormal screening liver function tests: serum bilirubin >= 1.5 x upper normal limit (ULN), alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) >= 2.5 x ULN (unless related to liver metastases in which case >= 5 x ULN).

• The following abnormal screening renal function tests: either a serum creatinine > 1.5 x ULN or a creatinine clearance (estimated from serum creatinine) < 40 mL/minute.

• Prior radiotherapy (except palliative).

• Participation in any investigational drug study or immunotherapy within 4 weeks preceding treatment start.

• History of hypersensitivity to sulphonamides.

• Any concurrent or previous malignancy of a different tumor type within 5 years of starting E7070 treatment except for adequately treated non-melanoma skin cancer or cervical intra-epithelial neoplasia.

• Significant disease, which in the Investigator's opinion would exclude the patient from the study.

• Surgically resectable metastatic disease.

• Legal incapacity.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma, Renal Cell
• Carcinoma
• Carcinoma, Renal Cell
• Kidney Neoplasms

Intervention

Drug:
• E7070

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Inc.

Countries where clinical trial is conducted

United States,  France, 

External Links

•   Link